8-K: Aytu BioPharma Reports FY26 Results, EXXUA Shows Growth

Aytu BioPharma announced fiscal 2026 fourth quarter results, with net revenue up 6.4% to $16.1 million, driven by EXXUA's commercial launch, while full-year revenue declined.

Summary

• Aytu BioPharma reported fiscal year 2026 and fourth quarter operational and financial results.
• Fourth quarter fiscal 2026 net revenue increased by 6.4% to $16.1 million compared to $15.1 million in the prior year quarter.
• EXXUA, the company's new drug for major depressive disorder, generated $3.9 million in net revenue in Q4 FY2026, its first full quarter of launch.
• Full-year fiscal 2026 net revenue decreased by 13.3% to $57.6 million from $66.4 million in fiscal 2025.
• The company reported a net loss of less than ($0.1) million for Q4 FY2026, a significant improvement from a net loss of ($19.8) million in Q4 FY2025.
• Full-year fiscal 2026 net loss was ($14.3) million, compared to ($13.6) million in the prior year.
• Adjusted EBITDA for Q4 FY2026 was $0.5 million, down from $2.0 million in the prior year quarter, reflecting investments in EXXUA.
• Full-year fiscal 2026 Adjusted EBITDA was ($3.7) million, compared to $9.2 million in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with positive momentum in EXXUA offsetting declines in legacy products, but significant investments impacting near-term profitability.

Positives

• Fourth quarter net revenue increased 6.4% to $16.1 million, showing sequential growth.
• EXXUA net revenue reached $3.9 million in its first full quarter of launch, with total prescriptions up 138% sequentially.
• Net loss in the fourth quarter was near break-even at less than ($0.1) million, a substantial improvement from the prior year.
• ADHD Portfolio net revenue increased sequentially to $10.4 million in Q4 FY2026.
• The company ended the quarter with a cash balance of $26.3 million.
• Management notes favorable early reimbursement dynamics for EXXUA.
• Prescriber adoption for EXXUA is broadening across different markets.
• Legacy business portfolios (ADHD and Pediatric) showed sequential improvement in Q4 FY2026.

Negatives

• Full-year net revenue decreased by 13.3% to $57.6 million.
• Full-year Adjusted EBITDA was negative at ($3.7) million, a significant drop from $9.2 million in the prior year.
• ADHD Portfolio net revenue decreased to $45.8 million for the full year, impacted by prioritization of EXXUA and generic competition.
• Pediatric Portfolio net revenue decreased to $5.1 million for the full year due to commercial prioritization of EXXUA.
• Operating expenses increased in Q4 FY2026 due to EXXUA commercialization investments.
• Gross profit margin decreased to 64.6% in Q4 FY2026 from 67.8% in the prior year quarter.
• A $2.2 million inventory write-down impacted full-year gross profit.

Risks

• The company is making planned investments towards the commercialization of EXXUA, which impacts current profitability.
• Generic competition continues to affect the ADHD Portfolio.
• The company's commercial prioritization of EXXUA has led to reduced promotion and revenue from legacy portfolios.
• EXXUA is in the early stages of launch, and prescribing, payer, and gross-to-net patterns will continue to evolve.
• The company faces risks associated with gaining market acceptance of its products.
• There are risks related to regulatory and compliance challenges.
• The company's overall financial and operational performance is subject to various risks and uncertainties.
• The company refers to risks described in Part I, Item 1A of its most recent Annual Report on Form 10K.

Future Outlook

The company believes it is increasingly well-positioned to drive sustained growth, build toward more consistent positive Adjusted EBITDA levels as fiscal 2027 progresses, and create long-term shareholder value, driven by EXXUA's progress and the durability of its legacy portfolios, coupled with disciplined expense management and a stable liquidity position.

Management Comments

• Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence in this exciting opportunity.
• EXXUA generated $3.9 million in net revenue during the quarter, up from $2.4 million in the third quarter, while more than 3,300 prescriptions were written, more than double the prior quarter.
• Our legacy business also delivered meaningful sequential improvement during the fourth quarter and continues to provide an important financial foundation supporting the EXXUA opportunity.
• The ADHD Portfolio remains highly profitable on a standalone basis and continues to be an important source of cash generation.
• Overall, we view the quarter as evidence of the operating leverage available in our model as EXXUA scales alongside the profitability and cash flow contribution from our legacy operations.
• Looking ahead, we are highly encouraged by EXXUAs progress, its differentiated profile and the significant opportunity within the more than $22 billion United States MDD market.
• When combined with the durability of our ADHD and Pediatric portfolios, disciplined expense management and a stable liquidity position, we believe Aytu is increasingly well positioned to drive sustained growth, build toward more consistent positive Adjusted EBITDA levels as fiscal 2027 progresses and create long-term shareholder value.

Industry Context

StockSavvy.ai notes that Aytu BioPharma's focus on CNS diseases, particularly with the launch of EXXUA for Major Depressive Disorder (MDD), places it in a significant and competitive market. The company's strategy of prioritizing EXXUA while managing its legacy ADHD and Pediatric portfolios reflects a common industry approach of balancing new product launches with established revenue streams, especially in the face of generic competition.

Comparison to Industry Standards

• The net revenue growth of 6.4% in the fourth quarter for Aytu BioPharma is modest compared to some high-growth biopharmaceutical companies, but is positive given the company's transition phase.
• The net loss of less than ($0.1) million in Q4 FY2026, while an improvement, indicates continued investment and is not yet indicative of sustained profitability seen in more mature pharmaceutical companies.
• The Adjusted EBITDA of $0.5 million in Q4 FY2026, though positive for the quarter, is a significant decrease from the prior year, highlighting the investment phase for EXXUA, which is typical for companies launching new drugs.
• The company's cash balance of $26.3 million provides a cushion but requires careful management given ongoing operational expenses and investment needs, a common challenge for mid-stage biopharma firms.

Stakeholder Impact

• Shareholders: The company's strategic shift towards EXXUA and the associated investments are aimed at long-term value creation, but near-term profitability is impacted, potentially affecting stock price.
• Employees: Continued investment in EXXUA commercialization may lead to increased focus and potential growth opportunities within the company.
• Patients: The launch of EXXUA offers a new treatment option for adults with major depressive disorder, with efforts to ensure patient access.
• Creditors: The company's cash position and ongoing revenue generation from legacy products are important for meeting financial obligations.

Next Steps

• Continue to drive EXXUA commercialization and adoption.
• Monitor and manage prescribing, payer, and gross-to-net patterns for EXXUA.
• Focus on disciplined and efficient commercial execution for EXXUA.
• Continue to support EXXUA investment through legacy portfolio performance.
• Work towards establishing EXXUA as an important treatment option for adults with major depressive disorder.
• Drive toward more consistent positive Adjusted EBITDA levels as fiscal 2027 progresses.

Key Dates

Recommendation

The company is in a transitional phase, with positive early signs for EXXUA but significant investments impacting profitability and a decline in legacy revenue. While the improved quarterly net loss is encouraging, the full-year results and negative Adjusted EBITDA indicate ongoing challenges. The stock is best held until there is clearer evidence of EXXUA's market penetration and a path to sustained profitability.

Keywords

pharmaceutical, CNS diseases, EXXUA, gepirone, major depressive disorder, ADHD, pediatric, revenue